A Pragmatic Approach Using First-Principle Methods to Address Site of Metabolism with Implications for Reactive Metabolite Formation
暂无分享,去创建一个
Ulf Norinder | Mats Svensson | Ya-Wen Hsiao | Carl Petersson | U. Norinder | M. Svensson | Y. Hsiao | C. Petersson | Carl Petersson
[1] S. Born,et al. Identification of the cytochromes P450 that catalyze coumarin 3,4-epoxidation and 3-hydroxylation. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[2] Angus Nedderman,et al. In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery. , 2008, Current drug metabolism.
[3] P M Shaw,et al. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. , 1997, The Journal of pharmacology and experimental therapeutics.
[4] R. Tukey,et al. Propranolol 4- and 5-hydroxylation and N-desisopropylation by cloned human cytochrome P4501A1 and P4501A2. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[5] Ping Zhao,et al. HUMAN IN VITRO GLUTATHIONYL AND PROTEIN ADDUCTS OF CARBAMAZEPINE-10,11-EPOXIDE, A STABLE AND PHARMACOLOGICALLY ACTIVE METABOLITE OF CARBAMAZEPINE , 2005, Drug Metabolism and Disposition.
[6] H. Yamazaki,et al. Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[7] R. Subramanian,et al. Bioactivation of a Novel 2-Methylindole-Containing Dual Chemoattractant Receptor-Homologous Molecule Expressed on T-Helper Type-2 Cells/d-Prostanoid Receptor Antagonist Leads to Mechanism-Based CYP3A Inactivation: Glutathione Adduct Characterization and Prediction of In Vivo Drug-Drug Interaction , 2010, Drug Metabolism and Disposition.
[8] T Ishizaki,et al. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. , 1997, The Journal of pharmacology and experimental therapeutics.
[9] F. Guengerich,et al. Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[10] P. C. Hariharan,et al. The influence of polarization functions on molecular orbital hydrogenation energies , 1973 .
[11] George S. Hammond,et al. A Correlation of Reaction Rates , 1955 .
[12] H. Yamazaki,et al. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. , 1994, Molecular pharmacology.
[13] Thomas Walle,et al. Oxidation of the flavonoids galangin and kaempferide by human liver microsomes and CYP1A1, CYP1A2, and CYP2C9. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[14] S. Shaik,et al. Alkane Hydroxylation by Cytochrome P450: Is Kinetic Isotope Effect a Reliable Probe of Transition State Structure? , 2000 .
[15] Y Ohno,et al. Metabolic activation of o-phenylphenol to a major cytotoxic metabolite, phenylhydroquinone: role of human CYP1A2 and rat CYP2C11/CYP2E1 , 2000, Xenobiotica; the fate of foreign compounds in biological systems.
[16] D. Morin,et al. Glutathione conjugation of electrophilic metabolites of 1-nitronaphthalene in rat tracheobronchial airways and liver: identification by mass spectrometry and proton nuclear magnetic resonance spectroscopy. , 1999, Chemical research in toxicology.
[17] J. Sutra,et al. Identification of human and rabbit cytochromes P450 1A2 as major isoforms involved in thiabendazole 5‐hydroxylation , 1998, Fundamental & clinical pharmacology.
[18] R J Edwards,et al. Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[19] Chris Oostenbrink,et al. Fast Prediction of Cytochrome P450 Mediated Drug Metabolism , 2009, ChemMedChem.
[20] G Ekström,et al. Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[21] Hao Chen,et al. Bioactivation of lamotrigine in vivo in rat and in vitro in human liver microsomes, hepatocytes, and epidermal keratinocytes: characterization of thioether conjugates by liquid chromatography/mass spectrometry and high field nuclear magnetic resonance spectroscopy. , 2010, Chemical research in toxicology.
[22] S Ohmori,et al. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. , 1994, Drug metabolism and disposition: the biological fate of chemicals.
[23] P. Beaune,et al. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[24] T Yamamoto,et al. Involvement of CYP1A2 in mexiletine metabolism. , 1998, British journal of clinical pharmacology.
[25] M. Myers,et al. Role of cytochrome P450 IA2 in acetanilide 4-hydroxylation as determined with cDNA expression and monoclonal antibodies. , 1991, Archives of biochemistry and biophysics.
[26] B. Lee,et al. The interpretation of protein structures: estimation of static accessibility. , 1971, Journal of molecular biology.
[27] S. Wrighton,et al. Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen. , 1995, Biochemical pharmacology.
[28] Michael Zientek,et al. Mechanism-Based Inactivation of Cytochrome P450 2C9 by Tienilic Acid and (±)-Suprofen: A Comparison of Kinetics and Probe Substrate Selection , 2009, Drug Metabolism and Disposition.
[29] H. DeLuca,et al. Isolation and identification of 5, 6-epoxyretinoic acid: a biologically active metabolite of retinoic acid. , 1978, Biochemistry.
[30] W. Trager,et al. Mechanism-based inactivation of cytochrome P450 2B1 by 8-methoxypsoralen and several other furanocoumarins. , 1998, Biochemistry.
[31] T. Shimada,et al. Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. , 1990, The Journal of pharmacology and experimental therapeutics.
[32] S K Balani,et al. In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4. , 1996, Chemical research in toxicology.
[33] M. Odomi,et al. Biotransformation of the novel inotropic agent toborinone (OPC-18790) in rats and dogs. Evidence for the formation of novel glutathione and two cysteine conjugates. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[34] Lars Ridder,et al. Mechanism and structure-reactivity relationships for aromatic hydroxylation by cytochrome P450. , 2004, Organic & biomolecular chemistry.
[35] Ilme Schlichting,et al. Structure and chemistry of cytochrome P450. , 2005, Chemical reviews.
[36] J E Leffler,et al. Parameters for the Description of Transition States. , 1953, Science.
[37] Mark Kao,et al. Metabolism and Excretion of RWJ-333369 [1,2-Ethanediol, 1-(2-Chlorophenyl)-, 2-carbamate, (S)-] in Mice, Rats, Rabbits, and Dogs , 2007, Drug Metabolism and Disposition.
[38] J P Perdrix,et al. Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. , 1998, British journal of anaesthesia.
[39] K. Uchino,et al. Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. , 1996, Biological & pharmaceutical bulletin.
[40] S. Born,et al. Synthesis and reactivity of coumarin 3,4-epoxide. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[41] Mark S. Gordon,et al. Self‐consistent molecular orbital methods. XXIII. A polarization‐type basis set for second‐row elements , 1982 .
[42] D. Swinney,et al. Isotopically labeled chlorobenzenes as probes for the mechanism of cytochrome P-450 catalyzed aromatic hydroxylation. , 1989, Biochemistry.
[43] A. D. Rodrigues,et al. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[44] S Udenfriend,et al. Hydroxylation-induced migration: the NIH shift. Recent experiments reveal an unexpected and general result of enzymatic hydroxylation of aromatic compounds. , 1967, Science.
[45] P Koch,et al. Biological fate of sirdalud in animals and man. , 1989, Xenobiotica; the fate of foreign compounds in biological systems.
[46] U. Hofmann,et al. Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4‐hydroxyantipyrine, 3‐hydroxymethylantipyrine, and norantipyrine formation , 1996, Clinical pharmacology and therapeutics.
[47] A. Somogyi,et al. Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms. , 1999, British journal of clinical pharmacology.
[48] J. Pople,et al. Self—Consistent Molecular Orbital Methods. XII. Further Extensions of Gaussian—Type Basis Sets for Use in Molecular Orbital Studies of Organic Molecules , 1972 .
[49] Xiaochao Ma,et al. METABOLISM OF MELATONIN BY HUMAN CYTOCHROMES P450 , 2005, Drug Metabolism and Disposition.
[50] H Chen,et al. Characterization of novel glutathione adducts of a non-nucleoside reverse transcriptase inhibitor, (S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-3, 4-dihydro-2(1H)-quinazolinone (DPC 961), in rats. Possible formation of an oxirene metabolic intermediate from a disubstituted alkyne. , 2000, Chemical research in toxicology.
[51] Ákos Tarcsay,et al. In silico site of metabolism prediction of cytochrome P450-mediated biotransformations , 2011, Expert opinion on drug metabolism & toxicology.
[52] R. Straka,et al. Evaluation of the Influence of Diabetes Mellitus on Antipyrine Metabolism and CYP1A2 and CYP2D6 Activity , 2000, Pharmacotherapy.
[53] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[54] D. Mansuy,et al. Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. , 1999, Biochemistry.
[55] G. Doss,et al. IDENTIFICATION AND METABOLISM OF A NOVEL DIHYDROHYDROXY-S-GLUTATHIONYL CONJUGATE OF A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONIST, MK-0767 [(±)-5-[(2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL]-2-METHOXY-N-[[(4-TRIFLUOROMETHYL) PHENYL]METHYL]BENZAMIDE], IN RATS , 2004, Drug Metabolism and Disposition.
[56] A. Becke. Density-functional thermochemistry. III. The role of exact exchange , 1993 .
[57] H K Kroemer,et al. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. , 1991, The Journal of pharmacology and experimental therapeutics.
[58] J. Bloomer,et al. In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[59] David C Evans,et al. EVIDENCE FOR THE BIOACTIVATION OF ZOMEPIRAC AND TOLMETIN BY AN OXIDATIVE PATHWAY: IDENTIFICATION OF GLUTATHIONE ADDUCTS IN VITRO IN HUMAN LIVER MICROSOMES AND IN VIVO IN RATS , 2006, Drug Metabolism and Disposition.
[60] Liang-Shang Gan,et al. Bioactivation of benzylamine to reactive intermediates in rodents: formation of glutathione, glutamate, and peptide conjugates. , 2002, Chemical research in toxicology.
[61] Jia-Sheng Wang,et al. Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract , 2006, International journal of cancer.
[62] Michael M. Mysinger,et al. Computational models for cytochrome P450: a predictive electronic model for aromatic oxidation and hydrogen atom abstraction. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[63] Gerald T Miwa,et al. Bioactivation of drugs: risk and drug design. , 2011, Annual review of pharmacology and toxicology.
[64] Chul-Ho Yun,et al. Kinetic deuterium isotope effects for 7‐alkoxycoumarin O‐dealkylation reactions catalyzed by human cytochromes P450 and in liver microsomes , 2006, The FEBS journal.
[65] Julian Blagg,et al. The Metabolism and Toxicity of Furosemide in the Wistar Rat and CD-1 Mouse: a Chemical and Biochemical Definition of the Toxicophore , 2007, Journal of Pharmacology and Experimental Therapeutics.
[66] Lars Olsen,et al. Prediction of activation energies for hydrogen abstraction by cytochrome p450. , 2006, Journal of medicinal chemistry.
[67] S. Clarke,et al. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[68] Parr,et al. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. , 1988, Physical review. B, Condensed matter.
[69] R. Hanzlik,et al. Premercapturic acid metabolites of bromobenzene derived via its 2,3- and 3,4-oxide metabolites. , 1991, Xenobiotica; the fate of foreign compounds in biological systems.
[70] Liang-Shang Gan,et al. Disposition of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'- (methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)- 1H-pyrazole-5-carboxamide (DPC 423) by novel metabolic pathways. Characterization of unusual metabolites by liquid chromatography/mass spectrometry and NMR. , 2002, Chemical research in toxicology.
[71] M. Bialer,et al. The Absorption, Metabolism, and Excretion of the Novel Neuromodulator RWJ-333369 (1,2-Ethanediol, [1-2-Chlorophenyl]-, 2-carbamate, [S]-) in Humans , 2007, Drug Metabolism and Disposition.
[72] S Udenfriend,et al. The role of arene oxide-oxepin systems in the metabolism of aromatic substrates. 3. Formation of 1,2-naphthalene oxide from naphthalene by liver microsomes. , 1968, Journal of the American Chemical Society.
[73] Gildas Bertho,et al. First evidence that cytochrome P450 may catalyze both S-oxidation and epoxidation of thiophene derivatives. , 2005, Biochemical and biophysical research communications.
[74] T. Baillie,et al. Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins. , 2003, Chemical research in toxicology.
[75] J. Tomasi,et al. Quantum mechanical continuum solvation models. , 2005, Chemical reviews.
[76] Lars Olsen,et al. Prediction of activation energies for aromatic oxidation by cytochrome P450. , 2008, The journal of physical chemistry. A.
[77] Chun Xing Li,et al. In vitro metabolism of the COX-2 inhibitor DFU, including a novel glutathione adduct rearomatization. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[78] Liang-Shang Gan,et al. Delineating novel metabolic pathways of DPC 963, a non-nucleoside reverse transcriptase inhibitor, in rats. Characterization of glutathione conjugates of postulated oxirene and benzoquinone imine intermediates by LC/MS and LC/NMR. , 2002, Chemical research in toxicology.
[79] T. Aoyama,et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. , 1992, Chemical research in toxicology.
[80] Zeruesenay Desta,et al. Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. , 2004, British journal of clinical pharmacology.
[81] D. Mansuy,et al. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. , 1995, Biochemistry.
[82] Vijay T. Ahuja,et al. Comparative Biotransformation of Pyrazinone-Containing Corticotropin-Releasing Factor Receptor-1 Antagonists: Minimizing the Reactive Metabolite Formation , 2010, Drug Metabolism and Disposition.
[83] Jeremy N. Harvey,et al. QM/MM modeling of benzene hydroxylation in human cytochrome P450 2C9. , 2008, The journal of physical chemistry. A.
[84] Yan Li,et al. Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. , 2011, Chemico-biological interactions.
[85] A Boobis,et al. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. , 1999, Biochemical pharmacology.